Total Payments
$565,250
2024 Payments
$182,242
Companies
27
Transactions
458
Medicare Patients
23,052
Medicare Billing
$7.1M
Payment Breakdown by Category
Other$275,007 (48.7%)
Consulting$240,429 (42.5%)
Travel$31,057 (5.5%)
Food & Beverage$11,163 (2.0%)
Research$7,563 (1.3%)
Education$32.26 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $272,382 | 104 | 48.2% |
| Consulting Fee | $240,429 | 101 | 42.5% |
| Travel and Lodging | $31,057 | 100 | 5.5% |
| Food and Beverage | $11,163 | 146 | 2.0% |
| Unspecified | $7,563 | 3 | 1.3% |
| Honoraria | $2,625 | 1 | 0.5% |
| Education | $32.26 | 3 | 0.0% |
Payments by Type
General
$557,688
455 transactions
Research
$7,563
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $164,731 | 119 | $0 (2024) |
| BeiGene USA, Inc. | $71,864 | 56 | $0 (2024) |
| Genmab U.S., Inc. | $65,028 | 56 | $0 (2024) |
| ABBVIE INC. | $53,340 | 60 | $0 (2024) |
| Kite Pharma, Inc. | $31,452 | 11 | $0 (2023) |
| Celgene Corporation | $31,282 | 32 | $0 (2024) |
| Lilly USA, LLC | $26,687 | 13 | $0 (2024) |
| Genentech USA, Inc. | $25,460 | 20 | $0 (2024) |
| Adaptive Biotechnologies Corporation | $23,017 | 31 | $0 (2024) |
| ADC Therapeutics America, Inc. | $13,034 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $182,242 | 138 | BeiGene USA, Inc. ($45,919) |
| 2023 | $166,503 | 128 | Kite Pharma, Inc. ($31,327) |
| 2022 | $69,563 | 60 | AstraZeneca Pharmaceuticals LP ($27,631) |
| 2021 | $39,926 | 39 | AstraZeneca Pharmaceuticals LP ($27,848) |
| 2020 | $64,728 | 34 | AstraZeneca Pharmaceuticals LP ($55,109) |
| 2019 | $40,148 | 54 | Celgene Corporation ($23,771) |
| 2018 | $2,044 | 4 | AstraZeneca Pharmaceuticals LP ($1,963) |
| 2017 | $97.68 | 1 | Celgene Corporation ($97.68) |
All Payment Transactions
458 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $3,181.45 | Research |
| Study: MorningSun | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $3,181.45 | Research |
| Study: MorningSun | ||||||
| 12/30/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | EPKINLY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $43.25 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $7.23 | General |
| 12/09/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 12/09/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $112.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $89.41 | General |
| Category: Oncology | ||||||
| 12/08/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 12/08/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $49.94 | General |
| Category: Oncology | ||||||
| 12/08/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $34.92 | General |
| Category: BioOncology | ||||||
| 12/07/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $71.63 | General |
| 12/07/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $141.29 | General |
| Category: Oncology | ||||||
| 11/19/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | Cash or cash equivalent | $246.56 | General |
| Category: Oncology | ||||||
| 11/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $377.36 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MorningSun | F. Hoffmann-La Roche AG | $6,363 | 2 |
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | Eli Lilly and Company | $1,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 65 | 5,415 | 102,931 | $4.0M | $1.4M |
| 2022 | 66 | 6,125 | 134,338 | $4.2M | $1.6M |
| 2021 | 64 | 5,499 | 117,604 | $4.1M | $1.6M |
| 2020 | 78 | 6,013 | 161,619 | $6.3M | $2.5M |
Total Patients
23,052
Total Services
516,492
Medicare Billing
$7.1M
Procedure Codes
286
All Medicare Procedures & Services
286 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 27 | 13,400 | $1.3M | $577,232 | 43.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 84 | 13,260 | $596,700 | $238,963 | 40.0% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 17 | 3,230 | $274,550 | $113,372 | 41.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 577 | 1,052 | $289,300 | $91,277 | 31.6% |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Office | 2023 | 14 | 2,480 | $272,800 | $89,920 | 33.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 127 | 380 | $133,000 | $35,520 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 157 | 271 | $100,270 | $34,812 | 34.7% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 13 | 372 | $364,560 | $30,819 | 8.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 73 | 194 | $42,680 | $17,060 | 40.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 407 | 1,131 | $31,668 | $11,685 | 36.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 140 | 548 | $46,580 | $11,532 | 24.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 74 | 74 | $30,340 | $10,906 | 35.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 416 | 1,300 | $37,700 | $9,878 | 26.2% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 27 | 6,630 | $28,178 | $9,112 | 32.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 380 | 1,012 | $10,120 | $8,484 | 83.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 120 | 142 | $26,980 | $8,071 | 29.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 51 | $20,910 | $6,587 | 31.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 76 | 140 | $33,600 | $6,381 | 19.0% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 21 | 15,300 | $22,950 | $5,958 | 26.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 40 | 123 | $21,525 | $5,710 | 26.5% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 105 | 615 | $18,450 | $5,577 | 30.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 166 | 432 | $21,600 | $4,236 | 19.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 68 | $13,260 | $3,515 | 26.5% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 14 | 17,280 | $17,280 | $3,052 | 17.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 35 | 135 | $10,800 | $2,769 | 25.6% |
About Dr. Tara Graff, DO
Dr. Tara Graff, DO is a Medical Oncology healthcare provider based in Clive, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2009. The National Provider Identifier (NPI) number assigned to this provider is 1356584080.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tara Graff, DO has received a total of $565,250 in payments from pharmaceutical and medical device companies, with $182,242 received in 2024. These payments were reported across 458 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($272,382).
As a Medicare-enrolled provider, Graff has provided services to 23,052 Medicare beneficiaries, totaling 516,492 services with total Medicare billing of $7.1M. Data is available for 4 years (2020–2023), covering 286 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Clive, IA
- Active Since 04/10/2009
- Last Updated 11/18/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1356584080
Products in Payments
- CALQUENCE (Drug) $169,707
- BRUKINSA (Drug) $68,253
- Epkinly (Drug) $64,919
- EPKINLY (Drug) $34,600
- clonoSEQ (Device) $22,983
- Yescarta (Drug) $18,870
- Revlimid (Drug) $16,389
- VENCLEXTA (Drug) $15,040
- Polivy (Biological) $13,600
- JAYPIRCA (Drug) $12,937
- MONJUVI (Drug) $11,085
- Lunsumio (Biological) $8,473
- Abraxane (Drug) $6,576
- BB-2121 (Drug) $5,031
- UKONIQ (Drug) $4,013
- XPOVIO (Drug) $2,760
- Poteligeo (Drug) $2,400
- ADCETRIS (Biological) $2,353
- Columvi (Biological) $2,055
- Rituxan (Drug) $1,800
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.